The EU-CARDIOPROTECTION COST Action (CA16225) is a pan-European research network of leading experts in experimental and clinical cardioprotection, whose overall aim is to improve the translation of novel experimental cardioprotective therapies into the clinical setting for patient benefit.
Myocardial stunning and hibernation revisitedFebruary 7, 2021 | General
New review article by Prof Gerd Heusch Nat Rev Cardiol. 2021 Feb 2. doi: 10.1038/s41569-021-00506-7. Abstract | Unlike acute myocardial infarction with reperfusion, in which infarct size is the end point reflecting irreversible injury, myocardial stunning and hibernation result from reversible myocardial ischaemia–reperfusion injury, and contractile dysfunction is the obvious end point. Stunned myocardium […]
7th EU-CARDIOPROTECTION COST Action Virtual MeetingFebruary 7, 2021 | General
Dear all Our next EU-CARDIOPROTECTION COST Action meeting will be a Virtual Meeting on Mar 11 2021 0830-1715 CET. Link to meeting program is below. 2021 7th COST Virtual Meeting 07022021 If you would like to attend please email me on [email protected] Best wishes Derek Hausenloy Chair of EU-CARDIOPROTECTION COST Action CA16225
[IJMS] Special Issue “Novel Molecular Targets for Cardioprotection 2020: The EU-CARDIOPROTECTION COST Action (CA16225)May 11, 2020 | General
In this Special Issue “Novel Molecular Targets for Cardioprotection 2020: The EU-CARDIOPROTECTION COST Action (CA16225)” of IJMS, we invite you to submit both review and original preclinical articles on the topic of cardioprotection, with a special focus on novel molecular targets for cardioprotection. Deadline for submission is Dec 31 2020.